These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21617596)

  • 21. Current concepts in antiretroviral therapy failure.
    del Rio C
    Top HIV Med; 2006; 14(3):102-6. PubMed ID: 16946454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [German-Austrian guidelines for antiretroviral therapy of HIV infection. (July, 2002, update)].
    Brockmeyer NH; ;
    Dtsch Med Wochenschr; 2003 May; 128 Suppl 1():S7-18. PubMed ID: 12736863
    [No Abstract]   [Full Text] [Related]  

  • 24. New guidelines provide greater flexibility in treating HIV.
    Strain W
    Posit Living; 1999 Jun; 8(5):6, 16. PubMed ID: 12492069
    [No Abstract]   [Full Text] [Related]  

  • 25. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Japanese guidelines for HIV infection].
    Ota Y
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():670-6. PubMed ID: 12722299
    [No Abstract]   [Full Text] [Related]  

  • 27. [Resistance screening].
    Sierra S; Lengauer T; Kaiser R
    MMW Fortschr Med; 2009 Apr; 151(18):72, 74-5. PubMed ID: 19769083
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].
    ;
    Dtsch Med Wochenschr; 2009 Jan; 134 Suppl 1():S4-15. PubMed ID: 19172554
    [No Abstract]   [Full Text] [Related]  

  • 30. Disappointing results for vicriviroc.
    AIDS Patient Care STDS; 2010 Mar; 24(3):197-8. PubMed ID: 20238442
    [No Abstract]   [Full Text] [Related]  

  • 31. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 32. HIV drug resistance and you. Resistance testing in experienced patients. Considerations when changing drugs.
    Posit Aware; 2006; Spec No():17-22. PubMed ID: 16596730
    [No Abstract]   [Full Text] [Related]  

  • 33. Rift over viral load data and clinical guidelines.
    Alcorn K
    J Int Assoc Physicians AIDS Care; 1997 Oct; 3(10):36-7. PubMed ID: 11364745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
    Lagnese M; Daar ES
    Expert Opin Pharmacother; 2008 Apr; 9(5):687-700. PubMed ID: 18345948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changing transmission fitness of drug-resistant human immunodeficiency virus against a background of evolving antiretroviral therapy.
    Murray JM
    J Infect Dis; 2003 Oct; 188(8):1258; author reply 1258-9. PubMed ID: 14551898
    [No Abstract]   [Full Text] [Related]  

  • 36. Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple.
    Razzolini F; Saladini F; Malincarne L; Vicenti I; Palladino N; Romano L; Francisci D; Zazzi M
    J Clin Microbiol; 2008 Nov; 46(11):3856-9. PubMed ID: 18845824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI; Aboulhab J
    HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New insights into HIV resistance testing: nursing guidelines and implications.
    Kirton CA; Kurtyka D; Sterken DJ
    J Assoc Nurses AIDS Care; 2007; 18(3):74-86. PubMed ID: 17570302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guideline watch. Antiretroviral drug resistance testing--updated guidelines from the IAS-USA.
    Hicks CB
    AIDS Clin Care; 2008 Aug; 20(8):64. PubMed ID: 18814369
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.